Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.

被引：0
|
作者：
Hao, Chunfang [1 ]
Wang, Xu [1 ]
Shi, Yehui [1 ]
Tong, Zhongsheng [1 ]
Li, Shufen [1 ]
Liu, Xiaodong [1 ]
Zhang, Lan [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：1
相关论文
共 50 条
  • [21] AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study.
    Dai Wangshu
    Qiu Xin
    Lu Changchang
    Zou Zhengyun
    Sha Huizi
    Kong Weiwei
    Liu Baorui
    Du Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [22] Chidamide combined with fulvestrant in the treatment of HR-positive and HER2negative advanced breast cancer after failure of previous endocrine therapy: A single-arm, single-center, phase 2 study
    Li, Wei
    Zou, La
    Zeng, Xiaohua
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
    Cao, F.
    Ma, Z.
    Hu, G.
    Zhu, X.
    Li, S.
    Chen, S.
    Chen, B.
    Li, Z.
    Wu, W.
    Ji, X.
    Shu, J.
    Tao, D.
    Hu, X.
    Zheng, M.
    Wang, O.
    Feng, Q.
    Hao, J.
    Li, X.
    BREAST, 2023, 68 : S16 - S16
  • [24] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [25] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [26] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [27] Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
    Montemurro, Filippo
    Donadio, Michela
    Clavarezza, Matteo
    Redana, Stefania
    Jacomuzzi, Maria Elena
    Valabrega, Giorgio
    Danese, Saverio
    Vietti-Ramus, Guido
    Durando, Antonio
    Venturini, Marco
    Aglietta, Massimo
    ONCOLOGIST, 2006, 11 (04): : 318 - 324
  • [28] Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
    Saura, Cristina
    Bendell, Johanna
    Jerusalem, Guy
    Su, Shaun
    Ru, Qinhua
    De Buck, Stefan
    Mills, David
    Ruquet, Sophie
    Bosch, Ana
    Urruticoechea, Ander
    Beck, Joseph T.
    Di Tomaso, Emmanuelle
    Sternberg, David W.
    Massacesi, Cristian
    Hirawat, Samit
    Dirix, Luc
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1935 - 1945
  • [29] The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial
    Wang, Wei
    Zhang, Juan
    Chang, Jin-Yi
    Yao, De-Shun
    Hu, Fen
    Liang, Yong -Ping
    Shen, Yan
    Liu, Yu-Qi
    Qi, Huai-Hua
    Tong, Jian-Bin
    Cai, Hai-Feng
    GLAND SURGERY, 2023, 12 (02) : 208 - 214
  • [30] Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.
    Hao, Chunfang
    Qi, Xiaowei
    Shi, Yehui
    Tong, Zhongsheng
    Zhang, Jie
    Meng, Wenjing
    Yang, Xiaonan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345